Clinical trial
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
- Lead sponsor
- Celgene
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- August 30, 2024
- Completion date
- November 27, 2028
- Enrollment
- 95 (actual)
- Sites
- 56
Conditions
As the registry lists them; a condition with its own page is linked.